Display options
Cite
Wagstaff AJ, Cheer SM, Matheson AJ, et al. Paroxetine: an update of its use in psychiatric disorders in adults. Drugs. 2002;62(4):655-703doi: 10.2165/00003495-200262040-00010.
Wagstaff, A. J., Cheer, S. M., Matheson, A. J., Ormrod, D., & Goa, K. L. (2002). Paroxetine: an update of its use in psychiatric disorders in adults. Drugs, 62(4), 655-703. https://doi.org/10.2165/00003495-200262040-00010
Wagstaff, Antona J, et al. "Paroxetine: an update of its use in psychiatric disorders in adults." Drugs vol. 62,4 (2002): 655-703. doi: https://doi.org/10.2165/00003495-200262040-00010
Wagstaff AJ, Cheer SM, Matheson AJ, Ormrod D, Goa KL. Paroxetine: an update of its use in psychiatric disorders in adults. Drugs. 2002;62(4):655-703. doi: 10.2165/00003495-200262040-00010. PMID: 11893234.
Copy Download .nbib Format: NLM
Share it on

Drugs. 2002;62(4):655-703. doi: 10.2165/00003495-200262040-00010.

Paroxetine: an update of its use in psychiatric disorders in adults.

Drugs

Antona J Wagstaff, Susan M Cheer, Anna J Matheson, Douglas Ormrod, Karen L Goa

Affiliations

  1. Adis International Limited, Auckland, New Zealand. [email protected]

PMID: 11893234 DOI: 10.2165/00003495-200262040-00010

Abstract

Paroxetine is a selective serotonin reuptake inhibitor (SSRI), with antidepressant and anxiolytic activity. In 6- to 24-week well designed trials, oral paroxetine 10 to 50 mg/day was significantly more effective than placebo, at least as effective as tricyclic antidepressants (TCAs) and as effective as other SSRIs and other antidepressants in the treatment of major depressive disorder. Relapse or recurrence over 1 year after the initial response was significantly lower with paroxetine 10 to 50 mg/day than with placebo and similar to that with imipramine 50 to 275 mg/day. The efficacy of paroxetine 10 to 40 mg/day was similar to that of TCAs and fluoxetine 20 to 60 mg/day in 6- to 12-week trials in patients aged > or =60 years with major depression. Paroxetine 10 to 40 mg/day improved depressive symptoms to an extent similar to that of TCAs in patients with comorbid illness, and was more effective than placebo in the treatment of dysthymia and minor depression. Paroxetine 20 to 60 mg/day was more effective than placebo after 8 to 12 weeks' treatment of obsessive-compulsive disorder (OCD), panic disorder, social anxiety disorder (social phobia), generalised anxiety disorder (GAD) and post-traumatic stress disorder (PTSD). Improvement was maintained or relapse was prevented for 24 weeks to 1 year in patients with OCD, panic disorder, social anxiety disorder or GAD. The efficacy of paroxetine was similar to that of other SSRIs in patients with OCD and panic disorder and similar to that of imipramine but greater than that of 2'chlordesmethyldiazepam in patients with GAD. Paroxetine is generally well tolerated in adults, elderly individuals and patients with comorbid illness, with a tolerability profile similar to that of other SSRIs. The most common adverse events with paroxetine were nausea, sexual dysfunction, somnolence, asthenia, headache, constipation, dizziness, sweating, tremor and decreased appetite. In conclusion, paroxetine, in common with other SSRIs, is generally better tolerated than TCAs and is a first-line treatment option for major depressive disorder, dysthymia or minor depression. Like other SSRIs, paroxetine is also an appropriate first-line therapy for OCD, panic disorder, social anxiety disorder, GAD and PTSD. Notably, paroxetine is the only SSRI currently approved for the treatment of social anxiety disorder and GAD, which makes it the only drug of its class indicated for all five anxiety disorders in addition to major depressive disorder. Thus, given the high degree of psychiatric comorbidity of depression and anxiety, paroxetine is an important first-line option for the treatment of major depressive disorder, OCD, panic disorder, social anxiety disorder, GAD and PTSD.

References

  1. Breast Cancer Res Treat. 2001 Nov;70(1):1-10 - PubMed
  2. BMJ. 1995 Jun 3;310(6992):1433-8 - PubMed
  3. Acta Psychiatr Scand. 1997 Feb;95(2):145-52 - PubMed
  4. Am J Psychiatry. 1998 Mar;155(3):367-72 - PubMed
  5. Br J Psychiatry. 1999 Aug;175:120-6 - PubMed
  6. J Clin Psychopharmacol. 1999 Apr;19(2):164-71 - PubMed
  7. Eur Neuropsychopharmacol. 2001 Aug;11(4):307-21 - PubMed
  8. Pharmacopsychiatry. 2001 May;34(3):85-90 - PubMed
  9. Prim Care Companion J Clin Psychiatry. 2001 Apr;3(2):44-52 - PubMed
  10. J Clin Psychopharmacol. 1997 Aug;17(4):267-71 - PubMed
  11. Acta Psychiatr Scand. 1988 Jun;77(6):683-8 - PubMed
  12. Acta Psychiatr Scand Suppl. 1989;350:85-6 - PubMed
  13. Am J Psychiatry. 1998 Oct;155(10):1346-51 - PubMed
  14. J Clin Psychiatry. 2001;62 Suppl 3:10-21 - PubMed
  15. Br J Psychiatry. 1999 Jul;175:12-6 - PubMed
  16. Psychopharmacol Bull. 1992;28(2):139-43 - PubMed
  17. J Psychopharmacol. 1998;12(3 Suppl B):S89-97 - PubMed
  18. Psychopharmacology (Berl). 1987;93(2):193-200 - PubMed
  19. Psychopharmacology (Berl). 1996 Jul;126(1):50-4 - PubMed
  20. J Clin Psychiatry. 2001 Nov;62(11):860-8 - PubMed
  21. Drugs. 1998 Jan;55(1):85-120 - PubMed
  22. J Clin Psychopharmacol. 1997 Jun;17(3):208-21 - PubMed
  23. J Affect Disord. 1990 Apr;18(4):289-99 - PubMed
  24. Acta Psychiatr Scand Suppl. 1989;350:60-75 - PubMed
  25. Pharmacopsychiatry. 1997 May;30(3):97-105 - PubMed
  26. J Clin Psychiatry. 1992 Feb;53 Suppl:48-51 - PubMed
  27. Int Clin Psychopharmacol. 1992 Jun;6 Suppl 4:37-41 - PubMed
  28. Psychopharmacol Bull. 1990;26(2):185-9 - PubMed
  29. Am J Psychiatry. 1998 Jan;155(1):36-42 - PubMed
  30. J Rheumatol. 2000 Dec;27(12):2791-7 - PubMed
  31. J Affect Disord. 2000 Aug;59(2):119-26 - PubMed
  32. Acta Psychiatr Scand. 1992 Dec;86(6):437-44 - PubMed
  33. Am J Psychiatry. 1999 Jul;156(7):1024-8 - PubMed
  34. South Med J. 1999 Sep;92(9):846-56 - PubMed
  35. J Clin Psychiatry. 2000;61 Suppl 5:60-6 - PubMed
  36. Pharmacopsychiatry. 1993 May;26(3):75-8 - PubMed
  37. J Affect Disord. 1993 Jun;28(2):71-9 - PubMed
  38. Br J Psychiatry. 1996 Oct;169(4):468-74 - PubMed
  39. J Clin Psychopharmacol. 1993 Dec;13(6 Suppl 2):18S-22S - PubMed
  40. Int Clin Psychopharmacol. 1997 Jan;12(1):13-8 - PubMed
  41. Acta Psychiatr Scand. 1997 Feb;95(2):153-60 - PubMed
  42. Am J Health Syst Pharm. 1998 Dec 1;55(23):2514-8 - PubMed
  43. Arch Gen Psychiatry. 2000 Sep;57(9):875-82 - PubMed
  44. Ann Clin Psychiatry. 1998 Dec;10(4):145-50 - PubMed
  45. J Clin Psychiatry. 1994 Dec;55 Suppl:48-58; discussion 59-60 - PubMed
  46. Biol Psychiatry. 1998 Jul 15;44(2):77-87 - PubMed
  47. Eur Neuropsychopharmacol. 1999 Jul;9 Suppl 3:S101-6 - PubMed
  48. N Engl J Med. 2000 Dec 28;343(26):1942-50 - PubMed
  49. Int Clin Psychopharmacol. 2001 May;16(3):169-78 - PubMed
  50. Am J Psychiatry. 2001 Dec;158(12):1982-8 - PubMed
  51. Acta Psychiatr Scand Suppl. 2000;403:39-49 - PubMed
  52. J Clin Psychiatry. 1992 Feb;53 Suppl:52-6 - PubMed
  53. JAMA. 1998 Aug 26;280(8):708-13 - PubMed
  54. Int J Geriatr Psychiatry. 1997 May;12(5):519-25 - PubMed
  55. Eur J Clin Pharmacol. 1997;53(3-4):163-9 - PubMed
  56. Prog Neuropsychopharmacol Biol Psychiatry. 1995 May;19(3):515-7 - PubMed
  57. J Clin Psychiatry. 1999;60 Suppl 16:3-76 - PubMed
  58. Hum Psychopharmacol. 2001 Apr;16(3):219-227 - PubMed
  59. Int Clin Psychopharmacol. 1998 Jul;13(4):169-74 - PubMed
  60. J Clin Psychiatry. 2001;62 Suppl 11:53-8 - PubMed
  61. J Clin Psychiatry. 1997 Jan;58(1):36-42 - PubMed
  62. J Clin Psychiatry. 1992 Feb;53 Suppl:40-3 - PubMed
  63. J Clin Psychiatry. 1998 May;59(5):229-32 - PubMed
  64. BMJ. 1999 May 1;318(7192):1188-91 - PubMed
  65. Aust N Z J Psychiatry. 1999 Jun;33(3):323-7 - PubMed
  66. Br J Psychiatry. 1991 Sep;159:394-8 - PubMed
  67. J Psychopharmacol. 1997;11(1):72-82 - PubMed
  68. Acta Psychiatr Scand Suppl. 1989;350:91-2 - PubMed
  69. J Fam Pract. 2001 May;50(5):405-12 - PubMed
  70. Drugs. 2000 Mar;59(3):497-509 - PubMed
  71. Drugs. 1991 Feb;41(2):225-53 - PubMed
  72. Am J Psychiatry. 1998 May;155(5 Suppl):1-34 - PubMed
  73. N Engl J Med. 2001 Mar 29;344(13):961-6 - PubMed
  74. J Clin Psychiatry. 1996;57 Suppl 2:46-52 - PubMed
  75. J Clin Psychiatry. 1998;59 Suppl 8:47-54 - PubMed
  76. J Affect Disord. 2002 May;69(1-3):119-40 - PubMed
  77. Br J Psychiatry. 1995 Sep;167(3):374-9 - PubMed
  78. Arch Gen Psychiatry. 1998 Dec;55(12):1121-7 - PubMed
  79. Depress Anxiety. 2001;13(1):38-44 - PubMed
  80. J Clin Psychopharmacol. 2000 Apr;20(2):137-40 - PubMed
  81. CNS Drugs. 1997 Aug;8(2):163-88 - PubMed
  82. Harv Rev Psychiatry. 1999 Jul-Aug;7(2):69-84 - PubMed
  83. J Clin Psychiatry. 1997 Jul;58(7):291-7 - PubMed
  84. Psychopharmacology (Berl). 1995 Jun;119(3):277-81 - PubMed
  85. Drug Saf. 1998 Jan;18(1):57-82 - PubMed
  86. J Clin Psychiatry. 1999 Dec;60(12):831-8 - PubMed
  87. J Clin Psychiatry. 2000 Mar;61(3):196-202 - PubMed
  88. Depress Anxiety. 2000;11(3):99-104 - PubMed
  89. J Clin Psychiatry. 1999;60 Suppl 20:16-20 - PubMed
  90. Acta Psychiatr Scand. 1993 May;87(5):302-5 - PubMed
  91. Arch Gen Psychiatry. 1994 Jan;51(1):8-19 - PubMed
  92. Int Clin Psychopharmacol. 2000 Aug;15 Suppl 2:S7-13 - PubMed
  93. S Afr Med J. 1999 Apr;89(4):402-6 - PubMed
  94. Br J Psychiatry. 2000 Apr;176:363-8 - PubMed
  95. J Clin Psychiatry. 1998;59 Suppl 20:73-84 - PubMed
  96. Eur Neuropsychopharmacol. 1998 Dec;8(4):273-8 - PubMed
  97. J Clin Psychiatry. 1994 Dec;55 Suppl:61-9; discussion 70-1 - PubMed
  98. Am J Psychiatry. 2000 Feb;157(2):185-9 - PubMed
  99. Br J Clin Pract. 1996 Jul-Aug;50(5):240-4 - PubMed
  100. J Clin Psychiatry. 1998;59 Suppl 17:54-60 - PubMed
  101. J Clin Psychiatry. 1999;60 Suppl 18:16-21 - PubMed
  102. J Clin Psychopharmacol. 1993 Dec;13(6 Suppl 2):34S-39S - PubMed
  103. Acta Psychiatr Scand. 1993 Feb;87(2):141-5 - PubMed
  104. Psychoneuroendocrinology. 2000 May;25(4):377-88 - PubMed
  105. J Clin Psychopharmacol. 1994 Aug;14(4):241-6 - PubMed
  106. Fam Pract. 1999 Apr;16(2):103-11 - PubMed
  107. Eur Neuropsychopharmacol. 1999 Jul;9 Suppl 3:S87-92 - PubMed
  108. Psychopharmacology (Berl). 1998 Apr;136(3):205-16 - PubMed
  109. J Clin Psychopharmacol. 2000 Dec;20(6):645-52 - PubMed
  110. J Clin Psychiatry. 1997 Mar;58(3):112-8 - PubMed
  111. Acta Psychiatr Scand. 1999 Sep;100(3):193-8 - PubMed
  112. J Affect Disord. 1999 Jul;54(1-2):39-48 - PubMed
  113. Int Clin Psychopharmacol. 2000 Jul;15(4):197-206 - PubMed
  114. J Clin Psychiatry. 2000 Nov;61(11):863-7 - PubMed
  115. Br J Psychiatry. 1999 Dec;175:591 - PubMed
  116. J Clin Psychiatry. 2001 May;62(5):350-7 - PubMed
  117. Gen Hosp Psychiatry. 1997 Mar;19(2):89-97 - PubMed
  118. Int Clin Psychopharmacol. 2000 Jul;15 Suppl 1:S13-7 - PubMed
  119. J Clin Psychiatry. 2000;61 Suppl 11:37-41 - PubMed
  120. Acta Psychiatr Scand Suppl. 1989;350:132-4 - PubMed
  121. Int J Geriatr Psychiatry. 1998 Feb;13(2):100-8 - PubMed
  122. Eur Neuropsychopharmacol. 1997 Oct;7 Suppl 3:S309-13 - PubMed
  123. Pharmacopsychiatry. 1998 May;31(3):89-101 - PubMed
  124. J Clin Psychiatry. 1999;60 Suppl 18:27-32 - PubMed
  125. Int Clin Psychopharmacol. 1993 Fall;8(3):189-95 - PubMed
  126. J Psychopharmacol. 1995 Jan;9(2 Suppl):163-78 - PubMed
  127. Int Clin Psychopharmacol. 1997 Mar;12(2):81-9 - PubMed
  128. Int Clin Psychopharmacol. 2000 Nov;15(6):305-18 - PubMed
  129. Acta Psychiatr Scand. 1996 Mar;93(3):158-63 - PubMed
  130. Clin Pharmacokinet. 1995;29 Suppl 1:1-9 - PubMed
  131. Acta Psychiatr Scand Suppl. 1989;350:89-90 - PubMed
  132. Encephale. 2001 Jan-Feb;27(1):71-81 - PubMed
  133. Acta Psychiatr Scand. 1997 May;95(5):444-50 - PubMed
  134. JAMA. 2000 Sep 27;284(12):1519-26 - PubMed
  135. J Clin Psychiatry. 1992 Feb;53 Suppl:57-60 - PubMed
  136. J Clin Psychopharmacol. 1993 Dec;13(6 Suppl 2):23S-27S - PubMed
  137. Int Clin Psychopharmacol. 1992 Jun;6 Suppl 4:59-64 - PubMed
  138. J Clin Psychiatry. 1997 Apr;58(4):146-52 - PubMed
  139. Am J Geriatr Psychiatry. 1998 Winter;6(1):83-9 - PubMed
  140. J Clin Psychiatry. 1997;58 Suppl 4:2-72 - PubMed

Substances

MeSH terms

Publication Types